Momenta Pharmaceuticals Inc. Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Momenta Pharmaceuticals Inc.

MNTA 52.48

0.0%

Oct 2 5:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: tom pope	11/4/2010 8:37:12 AM
	Read Replies (1) of 3027

Anti coagulants and prostate cancer. Men who have received a positive PSA test have many treatment options for dealing with their condition. However, the findings of a new study indicate that they are less likely to die from their condition regardless of whether they opt for radiation therapy or surgery if they take aspirin along with their treatment. Researchers from the University of Texas Southwestern Medical Center analyzed data from the Cancer of the Prostate Urological Research Endeavor to determine factors that might improve the survival rate in men whose cancer had not metastasized. They found that men who were taking anticoagulant medications, such as aspirin, reduced their risk of dying from their disease within 10 years from 10 percent to 4 percent. "Evidence has shown that anticoagulants may interfere with cancer growth and spread," said Kevin Choe, who led the study. "If the major effect of anticoagulants is preventing metastasis, this may be why previous clinical trials with anticoagulation medications produced mixed results, since most patients in these trials already had metastasis." Choe said that further clinical trials specific to prostate cancer should be conducted.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next